Literature DB >> 24709587

How advances in immunology provide insight into improving vaccine efficacy.

Mark K Slifka1, Ian Amanna2.   

Abstract

Vaccines represent one of the most compelling examples of how biomedical research has improved society by saving lives and dramatically reducing the burden of infectious disease. Despite the importance of vaccinology, we are still in the early stages of understanding how the best vaccines work and how we can achieve better protective efficacy through improved vaccine design. Most successful vaccines have been developed empirically, but recent advances in immunology are beginning to shed new light on the mechanisms of vaccine-mediated protection and development of long-term immunity. Although natural infection will often elicit lifelong immunity, almost all current vaccines require booster vaccination in order to achieve durable protective humoral immune responses, regardless of whether the vaccine is based on infection with replicating live-attenuated vaccine strains of the specific pathogen or whether they are derived from immunization with inactivated, non-replicating vaccines or subunit vaccines. The form of the vaccine antigen (e.g., soluble or particulate/aggregate) appears to play an important role in determining immunogenicity and the interactions between dendritic cells, B cells and T cells in the germinal center are likely to dictate the magnitude and duration of protective immunity. By learning how to optimize these interactions, we may be able to elicit more effective and long-lived immunity with fewer vaccinations.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; Immunological memory; Protection; Vaccination

Mesh:

Substances:

Year:  2014        PMID: 24709587      PMCID: PMC4096845          DOI: 10.1016/j.vaccine.2014.03.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  88 in total

1.  Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox.

Authors:  Erika Hammarlund; Matthew W Lewis; Shirley V Carter; Ian Amanna; Scott G Hansen; Lisa I Strelow; Scott W Wong; Paul Yoshihara; Jon M Hanifin; Mark K Slifka
Journal:  Nat Med       Date:  2005-08-07       Impact factor: 53.440

2.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

3.  Immunity to tetanus and diphtheria in the UK in 2009.

Authors:  Karen S Wagner; Joanne M White; Nick J Andrews; Ray Borrow; Elaine Stanford; Emma Newton; Richard G Pebody
Journal:  Vaccine       Date:  2012-09-26       Impact factor: 3.641

Review 4.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 5.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

6.  Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups.

Authors:  Masae Itoh; Yoshinobu Okuno; Hak Hotta
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

7.  Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.

Authors:  Fangjun Zhou; Jeanne Santoli; Mark L Messonnier; Hussain R Yusuf; Abigail Shefer; Susan Y Chu; Lance Rodewald; Rafael Harpaz
Journal:  Arch Pediatr Adolesc Med       Date:  2005-12

8.  The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.

Authors:  Rama S Akondy; Nathan D Monson; Joseph D Miller; Srilatha Edupuganti; Dirk Teuwen; Hong Wu; Farah Quyyumi; Seema Garg; John D Altman; Carlos Del Rio; Harry L Keyserling; Alexander Ploss; Charles M Rice; Walter A Orenstein; Mark J Mulligan; Rafi Ahmed
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Authors:  Alfred von Krempelhuber; Jens Vollmar; Rolf Pokorny; Petra Rapp; Niels Wulff; Barbara Petzold; Amanda Handley; Lyn Mateo; Henriette Siersbol; Herwig Kollaritsch; Paul Chaplin
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

10.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more
  41 in total

Review 1.  Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment.

Authors:  Dmitriy M Niyazov; Stephan G Kahler; Richard E Frye
Journal:  Mol Syndromol       Date:  2016-06-03

2.  A Learner-led, Discussion-based Elective on Emerging Infectious Disease.

Authors:  Clinton Mathias
Journal:  Am J Pharm Educ       Date:  2015-08-25       Impact factor: 2.047

3.  Current Status of Immunology Education in US Schools and Colleges of Pharmacy.

Authors:  Yuan Zhao; Dana Ho; Benjamin Oldham; Bonnie Dong; Daniel Malcom
Journal:  Am J Pharm Educ       Date:  2019-09       Impact factor: 2.047

4.  Long-Term Protection of Rhesus Macaques from Zika Virus Reinfection.

Authors:  Gage K Moreno; Christina M Newman; Michelle R Koenig; Mariel S Mohns; Andrea M Weiler; Sierra Rybarczyk; Kim L Weisgrau; Logan J Vosler; Nicholas Pomplun; Nancy Schultz-Darken; Eva Rakasz; Dawn M Dudley; Thomas C Friedrich; David H O'Connor
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

5.  Patching it together: epicutaneous vaccination with heat-labile Escherichia coli toxin against birch pollen allergy.

Authors:  S S Killingbeck; M Q Ge; A Haczku
Journal:  Allergy       Date:  2017-01       Impact factor: 13.146

6.  Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term.

Authors:  Leah C Katzelnick; Jose Victor Zambrana; Douglas Elizondo; Damaris Collado; Nadezna Garcia; Sonia Arguello; Juan Carlos Mercado; Tatiana Miranda; Oscarlett Ampie; Brenda Lopez Mercado; César Narvaez; Lionel Gresh; Raquel A Binder; Sergio Ojeda; Nery Sanchez; Miguel Plazaola; Krista Latta; Amy Schiller; Josefina Coloma; Fausto Bustos Carrillo; Federico Narvaez; M Elizabeth Halloran; Aubree Gordon; Guillermina Kuan; Angel Balmaseda; Eva Harris
Journal:  Sci Transl Med       Date:  2021-10-06       Impact factor: 17.956

7.  In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates.

Authors:  Grant C Weaver; Rina F Villar; Masaru Kanekiyo; Gary J Nabel; John R Mascola; Daniel Lingwood
Journal:  Nat Protoc       Date:  2016-01-07       Impact factor: 13.491

8.  CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice.

Authors:  Raphaël M Zellweger; William E Eddy; William W Tang; Robyn Miller; Sujan Shresta
Journal:  J Immunol       Date:  2014-09-12       Impact factor: 5.422

9.  Successful Vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Curr Top Microbiol Immunol       Date:  2018-07-26       Impact factor: 4.291

Review 10.  Plague vaccines: new developments in an ongoing search.

Authors:  Jason A Rosenzweig; Emily K Hendrix; Ashok K Chopra
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-18       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.